Narcotic Antagonists

"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents inhibiting the effect of narcotics on the central nervous system.

Descriptor ID	D009292
MeSH Number(s)	D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
Concept/Terms	Narcotic Antagonists Narcotic Antagonists Antagonists, Narcotic Opioid Receptor Antagonists Antagonists, Opioid Receptor Receptor Antagonists, Opioid Opioid Antagonists Antagonists, Opioid Competitive Opioid Antagonists Competitive Opioid Antagonists Antagonists, Competitive Opioid Opioid Antagonists, Competitive

Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Narcotic Antagonists [D27.505.696.543]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Narcotic Antagonists [D27.505.696.663.850.512]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Narcotic Antagonists [D27.505.954.427.550]

Below are MeSH descriptors whose meaning is related to "Narcotic Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.

Bar chart showing 65 publications over 26 distinct years, with a maximum of 9 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
1997	0	1	1
1998	1	0	1
1999	1	2	3
2000	1	1	2
2002	0	2	2
2003	1	1	2
2004	0	2	2
2005	1	0	1
2006	2	1	3
2007	1	1	2
2008	3	1	4
2009	1	1	2
2010	1	0	1
2011	5	4	9
2012	1	2	3
2013	0	4	4
2014	2	1	3
2016	0	1	1
2017	0	1	1
2019	2	1	3
2020	0	1	1
2021	0	2	2
2023	0	1	1
2024	1	4	5
2025	2	2	4

Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.

Shastry S, Carpenter J, Krotulski A, Brent J, Wax P, Aldy K, Campleman S, Culbreth R, Falise A, Hughes A, Hendrickson RG, Amaducci A, Judge B, Meaden C, Calello DP, Buchanan J, Shulman J, Levine M, Schwarz E, Manini AF. Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients. JAMA Netw Open. 2025 07 01; 8(7):e2518569.

View in: PubMed
Tata V, Varisco TJ, Rinker DV, Abughosh S, Rhodes C, Thornton JD. Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.

View in: PubMed
Iscoe MS, Diniz Hooper C, Levy DR, Buchanan L, Dziura J, Meeker D, Taylor RA, D'Onofrio G, Oladele C, Sarpong DF, Paek H, Wilson FP, Heagerty PJ, Delgado MK, Hoppe J, Melnick ER. Adaptive decision support for addiction treatment to implement initiation of buprenorphine for opioid use disorder in the emergency department: protocol for the ADAPT Multiphase Optimization Strategy trial. BMJ Open. 2025 Feb 20; 15(2):e098072.

View in: PubMed
Ovalles Lacruz A, Valle MS, Santoyo K, Clarke RD, Bhoite P, Alarcon LN. Empowering Future Physicians: Enhancing Naloxone Competency Through Early Harm Reduction Training in Medical Education. MedEdPORTAL. 2025; 21:11499.

View in: PubMed
Dicker F, Lothet E, Schwarz E, Aldy K, Brent J, Wax P, Culbreth R, Campleman S, Krotulski A, Logan B, Amaducci A, Judge B, Levine M, Calello D, Shulman J, Hughes A, Hendrickson RG, Meaden CW, Manini AF. Tramadol as a fentanyl adulterant: Prevalence and management in a ToxIC Fentalog study prospective cohort. Am J Emerg Med. 2025 Mar; 89:169-173.

View in: PubMed
Tatara E, Ozik J, Pollack HA, Schneider JA, Friedman SR, Harawa NT, Boodram B, Salisbury-Afshar E, Hotton A, Ouellet L, Mackesy-Amiti ME, Collier N, Macal CM. Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution. JAMA Netw Open. 2024 12 02; 7(12):e2448732.

View in: PubMed
Aldy K, Krotulski A, Brent J, Campleman S, Culbreth R, Logan B, Wax P, Amaducci A, Judge B, Levine M, Schwarz E, Calello DP, Meaden CW, Shulman J, Hughes A, Hendrickson R, Carpenter J, Buchanan J, Manini AF. Emergency Department Patients with Para-Fluorofentanyl Overdose. J Emerg Med. 2025 May; 72:56-69.

View in: PubMed
Abbasloo E, Esmaeili-Mahani S, Kobeissy F, Currier Thomas T. Evidence for the Induction of Analgesic Cross-Tolerance Between Opioid and Apelin/APJ Systems in Male Rats. J Stud Alcohol Drugs. 2024 Sep; 85(5):704-712.

View in: PubMed
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024 01 01; 81(1):45-56.

View in: PubMed
Brandt L, Hu MC, Liu Y, Castillo F, Odom GJ, Balise RR, Feaster DJ, Nunes EV, Luo SX. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023 05 01; 180(5):386-394.

View in: PubMed

People

Explore

Similar Concepts

Top Journals